Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
Andrea Citarella, Angela Scala, Anna Piperno, et al.
Biomolecules (2021) Vol. 11, Iss. 4, pp. 607-607
Open Access | Times Cited: 135

Showing 1-25 of 135 citing articles:

The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 148
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives
Gabriele La Monica, Alessia Bono, Antonino Lauria, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12500-12534
Open Access | Times Cited: 101
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 82
Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development
Zongyang Lv, Kristin E. Cano, Lijia Jia, et al.
Frontiers in Chemistry (2022) Vol. 9
Open Access | Times Cited: 77
Peptidomimetics: An Overview of Recent Medicinal Chemistry Efforts toward the Discovery of Novel Small Molecule Inhibitors
Giovanna Li Petri, Simona Di Martino, Maria De Rosa
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7438-7475
Closed Access | Times Cited: 73
Exploring pharmacological active ingredients of traditional Chinese medicine by pharmacotranscriptomic map in ITCM
Sai Tian, Jinbo Zhang, Shunling Yuan, et al.
Briefings in Bioinformatics (2023) Vol. 24, Iss. 2
Closed Access | Times Cited: 57
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 50
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
Bing Bai, Alexandr Belovodskiy, Mostofa Abu Hena, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2905-2925
Closed Access | Times Cited: 94
Recent Advances and Challenges in Gene Delivery Mediated by Polyester-Based Nanoparticles
Anna Piperno, Maria Teresa Sciortino, Elena Giusto, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 5981-6002
Open Access | Times Cited: 62
Artificial Intelligence Technologies for COVID-19 De Novo Drug Design
Giuseppe Floresta, Chiara Zagni, Davide Gentile, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3261-3261
Open Access | Times Cited: 45
Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents
Lara Alzyoud, Mohammad A. Ghattas, Noor Atatreh
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 2463-2478
Open Access | Times Cited: 42
In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease
Takashi Miura, Tika R. Malla, David Owen, et al.
Nature Chemistry (2023) Vol. 15, Iss. 7, pp. 998-1005
Open Access | Times Cited: 38
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery–Genetics Alliance Perspective
Cecilia Pozzi, Anne Vanet, Valeria Francesconi, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 6, pp. 3664-3702
Open Access | Times Cited: 28
Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
Andrea Citarella, Alessandro Dimasi, Davide Moi, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1339-1339
Open Access | Times Cited: 28
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 9
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
Bing Bai, Elena Arutyunova, Muhammad Bashir Khan, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 10, pp. 1722-1730
Open Access | Times Cited: 50
A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
Guillem Macip, Pol Garcia‐Segura, Júlia Mestres‐Truyol, et al.
International Journal of Molecular Sciences (2021) Vol. 23, Iss. 1, pp. 259-259
Open Access | Times Cited: 42
Deuterated Drugs and Biomarkers in the COVID-19 Pandemic
Ross D. Jansen‐van Vuuren, Luka Jedlovčnik, Janez Košmrlj, et al.
ACS Omega (2022) Vol. 7, Iss. 46, pp. 41840-41858
Open Access | Times Cited: 38
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine
Tika R. Malla, Lennart Brewitz, Dorian-Gabriel Muntean, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7682-7696
Open Access | Times Cited: 32
Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases
Simone Brogi, Roberta Ibba, Sara Rossi, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2561-2561
Open Access | Times Cited: 30
Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (Mpro) and Papain-like Protease (PLpro)
Folorunsho Bright Omage, Andrea Madabeni, Amanda Resende Tucci, et al.
Journal of Chemical Information and Modeling (2023) Vol. 63, Iss. 7, pp. 2226-2239
Open Access | Times Cited: 22
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 20
Synthesis of SARS-CoV-2 Mpro inhibitors bearing a cinnamic ester warhead with in vitro activity against human coronaviruses
Andrea Citarella, Davide Moi, Martina Pedrini, et al.
Organic & Biomolecular Chemistry (2023) Vol. 21, Iss. 18, pp. 3811-3824
Open Access | Times Cited: 19
On the origins of SARS-CoV-2 main protease inhibitors
Yves L. Janin
RSC Medicinal Chemistry (2023) Vol. 15, Iss. 1, pp. 81-118
Closed Access | Times Cited: 17
Non-peptidic inhibitors targeting SARS-CoV-2 main protease: A review
Ya-Qi Xiao, Jiao Long, Shuang‐Shuang Zhang, et al.
Bioorganic Chemistry (2024) Vol. 147, pp. 107380-107380
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top